Navigation Links
AMP releases statement on oversight of laboratory tests
Date:1/28/2010

Bethesda, MDJanuary 28, 2010 Today, the Association for Molecular Pathology (AMP) released its new position statement on the oversight of laboratory developed tests (LDTs), a recent focus of debate among policy makers, the laboratory community and other stakeholders. AMP's statement outlines the organization's commitment to providing high quality tests and its recognition of the need for implementation of appropriate oversight mechanisms. The association also met with officials from the United States Food and Drug Administration tasked with reviewing applications for diagnostic devices to inform them of the new position statement and discuss FDA's approach to regulating tests.

In recent years, there has been increased attention on the oversight of LDTs among policy makers, manufacturers, regulators and the laboratory community. While AMP believes that current mechanisms are sufficient in ensuring patient safety and broad access to high quality tests, AMP is taking this opportunity to elucidate its position on the issue.

"We believe that laboratory developed tests are an essential and central component of clinical care," said AMP President Dr. Karen Mann. She continued, "There is no evidence that the current oversight system has been inadequate or that there have been systemic problems."

In its position statement, AMP highlights that laboratories performing molecular tests are subject to the Clinical Laboratory Improvement Amendments and all laboratory directors are extensively trained professionals who adhere to all training requirements, certifications, licensure, and other regulations. Dr. Mann stressed the need to foster innovation, "As policymakers, regulators, and other stakeholders consider modifying the current oversight process, AMP urges them to ensure continued patient access to testing." AMP calls for stakeholders to avoid proposals that would hinder innovation in diagnostics, slow the rapid development and modification of necessary tests and impede the practice of medicine as all specialties rely on diagnostic tests.

AMP's specific recommendations include:

  • Laboratory directors or medical directors should review and reaffirm their policies and procedures for reviewing and documenting that appropriate validation studies have been performed for all tests developed in their laboratories with due consideration of clinical utility and clinical utilization.
  • CLIA should reassess utilization of resources and enforcement capabilities in order to meet its current mandate. CLIA should strengthen its enforcement capabilities by hiring more inspectors and improve the training of its inspectors.
  • To increase transparency, CMS should make information collected from laboratories in the CLIA program available and easily accessible to the public and other regulators.
  • Proficiency testing is a requirement of certification. When a formal proficiency testing program is not available, laboratories must perform and document alternative assessments as directed by CLIA.
  • Some tests may require greater scrutiny, such as those with hidden or nontransparent algorithms, and should be subject to additional review by regulators.
  • All LDTs should be subject to the same oversight mechanisms, and molecular tests should not be unduly scrutinized.
  • Any changes to the current oversight system should occur after a formal rule making process or statutory change.


'/>"/>

Contact: Mary Steele Williams
mwilliams@amp.org
301-634-7921
Association for Molecular Pathology
Source:Eurekalert

Related biology news :

1. Toxic releases down from North American industry leaders, increasing from other facilities
2. University of Minnesota releases first ever comprehensive report of the health of college students
3. WHRC releases 4 key reports
4. DOE JGI releases soybean genome assembly to enable worldwide bioenergy research efforts
5. DOE JGI releases a new version of its metagenome data management and analysis system
6. Wildlife Conservation Society releases definitive state of the wild
7. Pioneering landscape-scale research releases first findings
8. EPA releases science assessment on health effects of nitrogen oxides
9. EPA releases report on climate change and health
10. Neurotechnology Releases SentiSight 2.0 SDK Universal Object Recognition Technology
11. Neurotechnology Releases SentiSight 2.0 SDK Universal Object Recognition Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the latest release ... flexible and award winning eClinical solution, is now available ... is a proven Software-as-a-Service (SaaS) clinical research technology platform ... also delivers an entire suite of eClinical tools to ...
(Date:2/7/2017)... LONG BEACH, New York , February 7, 2017 ... formerly known as ID Global Solutions Corporation [OTC: IDGS], ... identification, identity management and electronic transaction processing services, is ... a reorganization of the Company. Effective January ... Chairman of the Board of Directors, CEO and President. ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... Island, NY (PRWEB) , ... February 24, 2017 , ... ... rate. Founded in late 2014, FireflySci had the goal of bringing their powerful ... that goal continues to shape the path that FireflySci is going on as they ...
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 /PRNewswire/ ... leading digital health company, and Digital Noema ... and remote patient monitoring, announce they are partnering ... DN Telehealth maximizes collaboration compatibility for ... consultations beyond a physical clinical setting to include ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring ... home or in healthcare facilities during periods of rest. A lightweight, non-invasive monitor ...
Breaking Biology Technology: